Royalty Pharma plc
RPRXNASDAQHealthcareBiotechnology
As of Oct 16, 2026 close
- Market cap
- $33.21B
- P/E (TTM)
- 40.75
- Forward P/E
- 51.12
- Dividend yield
- 1.55%
- 52-week range
- $35.79$64.38
- Volume (live)
- -
- Avg. volume (3M)
- 3.27M
Royalty Pharma (RPRX) Stock Price & Financial Analysis
Royalty Pharma Stock Price Chart
Loading chart...
Financial Metrics & Key Statistics
Fundamental metrics, valuation ratios, and profitability indicators
| Day's Range | $59.72 - $61.31 |
|---|---|
| 52-Week High | $64.38 |
| 52-Week Low | $35.79 |
| Open | $59.89 |
| Volume (last close) | 5.79M |
| Average Volume (3M) | 3.27M |
| Revenue (TTM) | 2.54B |
|---|---|
| Net Income (TTM) | 815.00M |
| Free Cash Flow (TTM) | 2.98B |
| EPS (TTM) | $1.46 |
| Profit Margin | 32.14% |
| Operating Margin | 62.35% |
| Return on Equity (ROE) | 8.33% |
| Debt to Equity | 0.92 |
| Annual Dividend | $0.93 |
|---|---|
| Dividend Yield | 1.55% |
| Payout Ratio | 63.27% |
| Last Dividend Ex-Date | Aug 14, 2026 |
| Market Cap | 33.21B |
|---|---|
| Shares Outstanding | 557.00M |
| P/E Ratio (TTM) | 40.75 |
| Forward P/E | 51.12 |
| Price to Sales (P/S) | 13.09 |
| Price to Book (P/B) | 3.39 |
| EV/EBITDA | 25.53 |
| 50-Day MA | $59.17 |
|---|---|
| 200-Day MA | $51.81 |
| 1-Year Change | +61.09% |
Source: Market prices and company fundamentals. Data as of Oct 16, 2026. Data sources and methodology
Royalty Pharma at a Glance
As of the Oct 16, 2026 close, Royalty Pharma (RPRX) has a market capitalization of $33.21B. The stock trades at 40.8× trailing earnings, 51.1× forward earnings and 13.1× sales. Over the trailing twelve months it earned $815.00M on revenue of $2.54B (a 32.1% profit margin) and generated $2.98B of free cash flow. Revenue grew 10.0% year over year.
As of its latest reported balance sheet, it holds $811.99M in cash and securities against $8.96B of debt, a net debt position of $8.15B.
Royalty Pharma pays a quarterly dividend totaling $0.93 per share a year, a 1.55% yield at the Oct 16, 2026 close, with a 63% payout ratio and 5 consecutive years of dividend increases.
The share price is up 61.1% over the past year. At $60.96 (the Oct 16, 2026 close) it sits near the top of its 52-week range of $35.79 to $64.38, above its 200-day moving average of $51.81.
Based on 8 professional analyst ratings from the past 90 days, the consensus is Buy with an average price target of $66.00, 8.3% above the Oct 16, 2026 close.
Frequently Asked Questions About Royalty Pharma
What is the current stock price for RPRX?
As of the Oct 16, 2026 close, RPRX stock trades at $60.96. The 52-week range is $35.79–$64.38, with a day range of $59.72–$61.31.
What is the P/E ratio for RPRX?
As of the Oct 16, 2026 close, Royalty Pharma's trailing twelve-month (TTM) P/E ratio is 40.8, meaning investors pay $40.8 for every $1 of annual earnings. The forward P/E is 51.1, reflecting analyst expectations for future earnings. Royalty Pharma operates in the Healthcare sector.
Does RPRX pay dividends?
Yes, Royalty Pharma pays a 1.55% annual dividend yield as of the Oct 16, 2026 close ($0.93 per share a year). The trailing twelve-month payout ratio is 63.3%. The most recent ex-dividend date was August 14, 2026.
What do analysts recommend for RPRX?
Based on ratings from 8 professional analysts over the last 90 days, the consensus for RPRX is Buy. The average 12-month price target is $66.00, a 8.3% upside from the Oct 16, 2026 close of $60.96.
What is the market cap of RPRX?
As of the Oct 16, 2026 close, Royalty Pharma's market capitalization is $33.95B, classifying it as a large-cap company. Royalty Pharma operates in the Healthcare sector within the Biotechnology industry.